Condition (MeSH)
Onycholysis
ClinicalTrials.gov lists 4 trials for Onycholysis or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
4 of the 4 trials are tagged with Onycholysis itself; the rest are tagged with a narrower condition beneath it.
When did Onycholysis trials start? (4)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 3
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2013 | 1 |
| 2011 | 1 |
| 2010 | 1 |
| 2005 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 4 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Onycholysis trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 2 |
| Observational | 1 |
How many Onycholysis trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 3 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Onycholysis trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pfizer | 2 |
| NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | 1 |
Which serious adverse events do Onycholysis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Coronary artery disease (unrelated) | 2 | 1 |
| Osteoarthritis (unrelated) | 2 | 1 |
| Pulmonary embolism (unrelated) | 2 | 2 |
| Acute myocardial infarction (unrelated) | 1 | 1 |
| Anaemia (unrelated) | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Onycholysis? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Distal phalangeal bone erosions observed by HR-pQCT in patients with psoriatic onycholysis. | Rheumatology (Oxford, England) | 2021 | Yes |
| A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy. | Breast cancer research and treatment | 2017 | Yes |
| Docetaxel-induced nail toxicity: a case of severe onycholysis and topic review. | Chinese medical journal | 2011 | Yes |
| Nail psoriasis: clinical presentation and best practice recommendations. | Drugs | 2009 | Yes |
| Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. | Cancer | 2008 | Yes |
Showing 5 of 8 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.